UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis

Caldeira, D; Rodrigues, FB; Duarte, MM; Sterrantino, C; Barra, M; Gonçalves, N; Pinto, FJ; ... Costa, J; + view all (2018) Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis. [Review]. Drug Safety , 41 (1) pp. 77-86. 10.1007/s40264-017-0586-2. Green open access

[thumbnail of Brogueira Rodrigues_Manuscrito Sofosbuvir 20170120 (2).pdf]
Preview
Text
Brogueira Rodrigues_Manuscrito Sofosbuvir 20170120 (2).pdf - Accepted Version

Download (3MB) | Preview

Abstract

INTRODUCTION: Sofosbuvir is a new direct-acting pyrimidine nucleotide analogue antiviral drug that has shown remarkable efficacy in the treatment of hepatitis C in clinical trials. However, observational anecdotal data have recently suggested an increased risk of serious bradycardia among patients treated with sofosbuvir and amiodarone. OBJECTIVE: We aimed to estimate and characterize the cardiac safety of sofosbuvir by performing a systematic review of randomized controlled trials (RCTs). METHODS: We conducted a systematic review of RCTs (PROSPERO 2016: CRD42016033109) comparing sofosbuvir and non-sofosbuvir regimens in patients with chronic hepatitis C by searching the MEDLINE, Embase, and Cochrane Library databases up to January 2017. Non-published data were obtained from the sofosbuvir marketing authorization holder. Random-effects meta-analysis was performed to derive pooled estimates of relative risks (RRs) and corresponding 95% confidence intervals (CIs). RESULTS: Six trials, enrolling 2346 patients (1625 treated with sofosbuvir), were included. The overall risk of bias across studies was moderate. The risk of reported cardiac events (RR 0.87; 95% CI 0.41-1.85), arrhythmias (RR 0.93; 95% CI 0.34-2.51), bradycardia (RR 0.47; 95% CI 0.04-5.20), and tachycardia (RR 0.91; 95% CI 0.20-4.20) were not significantly different between sofosbuvir and non-sofosbuvir regimens. The risks of reported syncope, presyncope, loss of consciousness, or palpitations were similar among those receiving sofosbuvir regimens and controls. CONCLUSIONS: The pooled data from RCTs did not show an increased risk of cardiac outcomes, including arrhythmias (and bradycardia), among sofosbuvir-treated patients, although the overall quality of the evidence supporting this conclusion was very low.

Type: Article
Title: Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis
Location: New Zealand
Open access status: An open access version is available from UCL Discovery
DOI: 10.1007/s40264-017-0586-2
Publisher version: http://dx.doi.org/10.1007/s40264-017-0586-2
Language: English
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/1569673
Downloads since deposit
253Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item